Altimmune, Inc. (FWB:3G0) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and accompanying common stock warrants (or pre-funded warrants in lieu thereof) Closed: US$225M raised · US$3 a share · Warrants at US$3 · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Barclays (co-lead), Titan Partners (co-lead) Buyers: Deep Track Capital (led the financing); TCGX; Viking Global Investors; RA Capital Management Use of proceeds: Fund the upcoming Phase 3 trial in MASH, plus working capital and general corporate purposes | Apr 27, 2026 |
| Registered direct offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$75M raised · Titan Partners, a division of American Capital Partners Dealers: Titan Partners, a division of American Capital Partners (lead) Buyers: new fundamental institutional investor (17,045,454 shares of common stock (or pre-funded warrants in lieu thereof)) Use of proceeds: Upcoming Phase 3 trial in MASH, working capital and general corporate purposes | Jan 29, 2026 |